Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

53.48 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Price and Volume

Volume	0
Open	-
Bid (Size)	51.80 (100)
Ask (Size)	54.75 (300)
Prev. Close	53.48
Today's Range	53.48 - 53.48
52wk Range	13.22 - 94.90
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring

April 02, 2026

Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require...

Via MarketMinute

Main Street’s Revenge: The Great Rotation of 2026 Rewrites Market History

March 26, 2026

The financial landscape of 2026 has been defined by a singular, tectonic shift that few predicted would be this absolute: the definitive end of the mega-cap tech era and the roaring resurgence of the...

Via MarketMinute

Performance

YTD	-21.5%	-21.5%
1 Month	-15.2%	-15.2%
3 Month	-21.5%	-21.5%
6 Month	+100.9%	+100.9%
1 Year	+215.5%	+215.5%

More News

The Great Rotation: Small-Caps Seize Market Leadership in Historic 2026 Breakout

March 25, 2026

Via MarketMinute

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗

January 14, 2026

Via Stocktwits

The Great Rotation: Russell 2000 Outshines Mega-Caps as Domestic Small-Caps Take the Reins in 2026

March 24, 2026

Via MarketMinute

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗

March 22, 2026

Via The Motley Fool

3 Companies at the Forefront of the GLP-1 Pill Wars ↗

March 16, 2026

Via MarketBeat

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

March 16, 2026

From Structure Therapeutics Inc.

Via GlobeNewswire

Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗

February 27, 2026

Via The Motley Fool

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

February 27, 2026

Via Finterra

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

February 26, 2026

From Structure Therapeutics Inc.

Via GlobeNewswire

Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗

February 25, 2026

Via The Motley Fool

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

Via The Motley Fool

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗

February 25, 2026

Via The Motley Fool

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

February 17, 2026

Via MarketMinute

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Via The Motley Fool

Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition

February 06, 2026

Via MarketMinute

This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs. ↗

February 05, 2026

Via The Motley Fool

A 10% Owner Of Structure Therapeutics Shed Shares ↗

January 13, 2026

Via The Motley Fool

Can This Stock Double Again in 2026? ↗

January 11, 2026

Via The Motley Fool

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

Via MarketMinute

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗

January 05, 2026

Via Stocktwits

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Via MarketMinute

The Case for Small-Cap Diversification: Why Investors are Looking Beyond Mega-Cap Tech

December 23, 2025

Via MarketMinute

Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts

December 23, 2025

Via MarketMinute

Frequently Asked Questions

Is Structure Therapeutics Inc. - American Depositary Shares publicly traded?

Yes, Structure Therapeutics Inc. - American Depositary Shares is publicly traded.

What exchange does Structure Therapeutics Inc. - American Depositary Shares trade on?

Structure Therapeutics Inc. - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Structure Therapeutics Inc. - American Depositary Shares?

The ticker symbol for Structure Therapeutics Inc. - American Depositary Shares is GPCR on the Nasdaq Stock Market

What is the current price of Structure Therapeutics Inc. - American Depositary Shares?

The current price of Structure Therapeutics Inc. - American Depositary Shares is 53.48

When was Structure Therapeutics Inc. - American Depositary Shares last traded?

The last trade of Structure Therapeutics Inc. - American Depositary Shares was at 04/02/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.